Status:

COMPLETED

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma

Lead Sponsor:

ARS Pharmaceuticals, Inc.

Conditions:

Asthma

Eligibility:

All Genders

12-65 years

Phase:

PHASE2

Brief Summary

ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.

Eligibility Criteria

Inclusion

  • 1\. Is a male or female subject between the ages of 12 and 65 years, inclusive.
  • 2\. Asthma that has been stable for at least four weeks prior to screening as defined by clinical history.
  • 3\. Reversible bronchoconstriction.
  • 4\. Has body weight more than 30 kilogram (kg) and body mass index between 18 and 34 kg/m², inclusive.
  • 5\. Has no medical history of hypertension and cardiovascular disease in the last 10 years.
  • 6\. At screening, has stable vital signs.

Exclusion

  • 1\. History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition.
  • 2\. Patients receiving beta blocker.
  • 3\. Has any clinically significant medical condition or physical exam finding as deemed inappropriate by the Investigator.
  • 4\. Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal electrocardiogram.
  • 5\. Has mucosal inflammatory disorders.
  • 6\. Has had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening.

Key Trial Info

Start Date :

July 28 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 2 2024

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT05363670

Start Date

July 28 2022

End Date

February 2 2024

Last Update

July 30 2024

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

University of South Florida

Tampa, Florida, United States, 33613

2

Institute for Asthma and Allergy

Chevy Chase, Maryland, United States, 20815

3

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

4

Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, United States, 45236

Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma | DecenTrialz